Home Tags Trastuzumab deruxtecan

Tag: Trastuzumab deruxtecan

Gesso Italiano (Italian Chalk) in San Diego's Little Italy neighborhood celebrating its heritage by bringing the vibrancy and flavors of Italy to southern California. Courtesy: 2016 Fotolia.

Advanced Design of ADCs: Principles and Applications using Next Generation Linkers...

Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right target, right antibody, right linker,...

Highlights in Development: September 2019

In September 2019, a number of articles discussing antibody-drug conjugates were published in a variety of journals.  Here is an overview of some of...
Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

Encouraging Preliminary Results in Treatment of Colorectal Cancer with Trastuzumab Deruxtecan

Updated Phase I safety and efficacy data for [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody-drug conjugate or ADC, were presented at the 2018 annual congress of the European Society for Medical Oncology - ESMO 2018, in Munich, Germany for a subgroup of patients with heavily pretreated HER2 expressing colorectal cancer.

Updated Results for [Fam-] Trastuzumab Deruxtecan in Patients with HER2 Mutated...

Updated phase I safety and efficacy data for trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC) being developed by Daiichi...

New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors Warrants Further...

In clinical trials, trastuzumab deruxtecan or DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated preliminary antitumor activity in...